

Meeting of the Interagency Autism Coordinating Committee

October 26, 2016

National Institutes of Health
31 Center Drive
Building 31, C Wing, 6th Floor, Conference Room 6
Bethesda, MD 20892

Conference Call Access:

Phone: 888-469-2037

Access Code: 3353029

Meeting of the IACC

Morning Agenda

**9:00 AM Welcome, Introductions, Roll Call and
Approval of Minutes**

Joshua Gordon, M.D., Ph.D.
Director, NIMH and Chair, IACC

Bruce Cuthbert, Ph.D.
Director, Research Domain Criteria Unit,
NIMH

Susan Daniels, Ph.D.
Director, OARC, NIMH and Executive
Secretary, IACC

Meeting of the IACC

Morning Agenda – continued

**10:00 Update from Office of the National
Autism Coordinator**

Thomas Novotny, M.D.
Deputy Assistant Secretary for Health and
National Autism Coordinator
Department of Health and Human Services

10:05 Tackling Early Death in Autism

Jon Spiers
Chief Executive
Autistica, United Kingdom

Meeting of the IACC

Morning Agenda - continued

**10:05 Tackling Early Death in Autism –
 continued**

James Cusack, Ph.D.
Director, Science
Autistica, United Kingdom

10:55 Morning Break

Tackling early death in autism

Dr James Cusack & Jon Spiers, October 2016

AUTISTICA
Building brighter futures through autism research

About Autistica

- The UK's leading autism research charity
- We want to give everyone affected by autism the chance of a **long, happy, healthy life**
- Our research strategy is driven by the views of the autism community

Overview

- The data on mortality in autism
- New research directions
- Autistica's report and campaign
- Policy, information and awareness
- Developing a global response

Data on mortality


- The largest ever autism mortality study (ASD n = 27,122; matched controls n = 2,672,185) was recently published, finding increased risk of early death in autism, OR:2.56 (2.38-2.76) (Hirvikoski et al., 2015).
- Autistic and intellectually disabled at highest risk of early death (OR: 5.78) with neurological conditions (epilepsy) the leading cause (OR: 40.56)
- In autistic people with no intellectual disability increased risk of death is also found (OR: 2.18) with suicide being a leading cause (OR:9.40).

Study	Country	Total n ASD	Risk ratio
Mouridsen	Denmark	341	1.9 (1.3-2.8)
Pickett	USA	13111	2.5
Gillberg	Sweden	120	5.6 (2.5-10.5)
Bilder	USA	305	9.9 (5.7-17.2)
Schendel	Denmark	20,492	2.0 (1.4-3.0)

Data from other studies on mortality

Autism and epilepsy

- 20-40% of autistic people also end up having epilepsy (Bolton et al., 2011)
- Altered developmental trajectory, often occurring later.
- Seizures may be more frequent in frontal lobe/social centres, resistant to treatment, harder to identify.



Mental Health and Suicide

- Autistic children are at increased risk of mental health problems: 70% having one; 40% having two or more (Simonoff et al., ,2008). Approximately half of 5-10 year olds have an anxiety disorder.
- 80% of adults have reported having a psychiatric disorder. 57.2% reported having depression, 53.2% anxiety (Lever & Geurts, 2016)
- 66% of autistic adults with no intellectual disability have considered suicide. 35% have made plans or attempts at suicide (Cassidy et al., 2014).

Other causes of death

Autistic people experience worse physical health than the general population and are at significantly increased risk of heart disease, stroke, diabetes and respiratory conditions.

Causes are complex and poorly understood but likely to be multi-factorial.

Causes	Odds Risk
Circulatory	1.49 (1.27-1.75)
Congenital	19.10 (11.94-30.55)
Digestive	3.31 (2.25-4.87)
Endocrine	3.70 (2.34-5.87)
Neoplasms	1.80 (1.46-2.23)
Respiratory	2.68 (1.99-3.62)

Hirvikoski et al., 2015

Illnesses	Odds Risk
Cardiovascular disease	2.54 (2.13-3.02)
Diabetes	2.18 (1.62-2.93)
Parkinson's	32.73 (7.76-137.96)
Stroke	2.12 (1.03-4.37)


Croen et al., 2015

Autistica's scientific response



We aim to raise and leverage **£10m** in five years to fund new research into epilepsy, suicide and the other major causes of death for autistic people.

Autistica's scientific response




The need for a global response

We cannot tackle this enormous challenge alone.

Autistica has committed to raise awareness of this shocking situation, first in the UK and Europe and now internationally.

Our first report in March 2016 aimed to:

- Raise awareness of the hidden mortality crisis
- Increase other funders' investment in research
- Ensure services actively reduce premature death
- Make recommendations for action by politicians



Influencing policymakers

We are calling for:

- Premature deaths in autism to be a national priority
- Better data collection and analysis
- Better support for autistic people (health checks, risk plans, screening, new therapies)
- More training for healthcare professionals
- More research



Influencing policymakers

In the UK, we have:

- Secured autism as a theme in a National Mortality Review
- Published a Parliamentary Commission report on early death and access to healthcare
- Improved autism data collection by doctors
- Integrated autism into the National Suicide Prevention Alliance and a national suicide enquiry
- Met leading politicians and civil servants
- Held a three hour debate in Parliament

Awareness

Over 120 newspapers, TV and radio stations and news websites have covered the issue

We briefed the leading UK autism charities and presented our report at Autism Europe Congress 2016

We continue to spread the word nationally and internationally



Information

This is new to the vast majority of the autism community

We must take care how and when we communicate the risks, be clear on what we do and don't yet know, and be sensitive to autistic people's needs

We are soon to publish new information resources for individuals and families



Driving a global response

Together, we should be aiming to give everyone affected by autism the chance of a long, happy, healthy life

- New basic, translational and epidemiological studies
- International collaborations to accelerate progress
- Open source resources for the autism community
- Coordinated policy responses



AUTISTICA

Building brighter futures through autism research

Thank you.

james.cusack@autistica.org.uk
jon.spiers@autistica.org.uk

www.autistica.org.uk

Meeting of the IACC

Break

Meeting of the IACC

Morning Agenda - continued

11:10 Committee Business

Susan Daniels, Ph.D.

Director, Office of Autism Research
Coordination, NIMH and Executive
Secretary, IACC

IACC Strategic Plan Update

- Update on working group activities
- Discussion of duplication of effort statement
- Discussion of budgetary requirements
- Discussion of objective development

12:00 PM Lunch

Meeting of the IACC

Committee Business

Susan Daniels, Ph.D.

Director, Office of Autism Research Coordination, NIMH
and Executive Secretary, IACC

IACC Committee Business

Susan A. Daniels, Ph.D.

Director, Office of Autism Research Coordination

Executive Secretary, IACC




National Institute of Mental Health

IACC Full Committee Meeting


October 26, 2016

IACC Responsibilities

- Develop and annually update a strategic plan for ASD
- Develop and annually update a summary of advances in ASD research
- Monitor Federal activities with respect to ASD
- Make recommendations to the HHS Secretary regarding research or public participation in decisions regarding ASD



IACC Strategic Plan Update



Seven working groups composed of IACC Members and invited external experts have been convened to cover the 7 Strategic Plan Questions

IACC Strategic Plan Working Groups

- Question 1: When Should I Be Concerned? **(Screening/Diagnosis)**
- Question 2: How Can I Understand What Is Happening? **(Underlying Biology)**
- Question 3: What Caused This to Happen and Can It Be Prevented? **(Risk Factors)**
- Question 4: Which Treatments and Interventions Will Help? **(Interventions)**
- Question 5: Where Can I Turn for Services? **(Services)**
- Question 6: What Does the Future Hold, Particularly for Adults? **(Lifespan Issues)**
- Question 7: What Other Infrastructure and Surveillance Needs Must Be Met? **(Infrastructure, Surveillance, Outreach, Collaboration)**

Working Group Activities

Each of the 7 working groups held 2 conference calls in September and October to discuss:

- **Progress toward the current Strategic Plan Objectives**
 - Based on information from the 2013 analysis of research funded by federal and private funders
- **Progress in the field:**
 - Research advances
 - Practice to research
 - Gaps, needs, barriers and opportunities
 - New programs and policies
 - New research evidence that can inform policy
 - Services needs/gaps, needed policy changes
- **Aspirational Goal; Chapter Title**

Working Group Activities

Each of the 7 working groups is in the process of or has already scheduled a third conference call where we will discuss:

- **Draft chapter outline for each Question that describes progress in the field, gaps/needs, barriers and opportunities**
- **Development of 3 broad objectives for each Question, including examples of responsive research projects, and services or policy activities**
- ***Today: IACC suggestions re: areas to target in objectives?***

Strategic Plan Update Requirements

- **The Autism CARES Act requires the IACC in its Strategic plan to provide:**
 - “Recommendations to ensure that autism spectrum disorder research, and services and support activities to the extent practicable, of the Department of Health and Human Services and of other Federal departments and agencies are not unnecessarily duplicative.”**
- **This requirement was based on a 2013 report by the GAO that stated concerns about potential for duplication in the research portfolio, but not services**
- **IACC public members responded to the report**

Strategic Plan Update Requirements

- **IACC Public Member Response Letter Key Points:**
 - **Efforts by multiple agencies with different mission areas to address different aspects of broad, complex issues related to autism spectrum disorders research is important and necessary**
 - **Emphasized the need for corroboration and replication of research**

Strategic Plan Update Requirements

- **Feedback collected from working groups regarding duplication:**
 - **Emphasized the importance of replication of research and reproducibility**
 - **Saw role for closer coordination of large genomic sequencing efforts to avoid resequencing same individuals, more transparency and data sharing to prevent duplication of effort**
 - **Ensuring that the new Strategic Plan objectives have minimal overlap will make it easier to review the portfolio for potential duplication**
 - ***Other suggestions from the committee?***

Strategic Plan Update Requirements

- **Next steps:**
 - **IACC needs to prepare a 1-2 paragraph statement on recommendations to ensure that unnecessary duplication of effort is minimized**
 - **Volunteer(s) to draft a statement for feedback from the working groups and then review by the full committee in January?**
 - **Text of IACC letter is available as a resource**

Strategic Plan Update Requirements

- **The Autism CARES Act requires the IACC Strategic Plan to include “proposed budgetary requirements.”**
- **The previous Strategic Plan provided estimated budgetary requirements for each objective**
- ***Does the committee want to develop budgetary requirements based on the objectives, the questions, or the overall plan, keeping in mind that the new objectives will be broad and inclusive of both research and services activities?***
- ***Does the committee want to try to estimate actual budgets or project percentage increases, decreases, etc.? Growth over time?***

Strategic Plan Next Steps

- **Working Group Calls to be held in November**
- **Working groups to begin writing chapters in November**
- **Chapter drafts will be shared with committee in January, with goal of publication of new Strategic Plan in April 2017**

OFFICE OF
**AUTISM RESEARCH
COORDINATION**
.....
NATIONAL INSTITUTES OF HEALTH

Susan Daniels, Ph.D., Director

Ben Feldman, Ph.D., Science Policy Analyst

Angelice Mitrakas, B.A., Operations Coordinator

Karen Mowrer, Ph.D., Science Policy Analyst

Miguelina Perez, B.A., Management Analyst

Julianna Rava, M.P. H., Science Policy Analyst

Jeff Wiegand, B.S., Web Development Manager

Meeting of the IACC

Lunch

Meeting of the IACC

Afternoon Agenda

- 1:00** **Oral Public Comment Session**
-
- 1:30** **Summary of Written Public Comments**
Karen Mowrer, Ph.D.
Health Science Policy Analyst
OARC, NIMH
-
- 1:40** **Request for Public Comment**
Susan Daniels, Ph.D.
Director, OARC and Executive Secretary,
IACC
-
- 1:45** **IACC Committee Member Discussion of**
Public Comments

Meeting of the IACC

Oral Comments Session

Meeting of the IACC

Afternoon Agenda

- 1:00** **Oral Public Comment Session**
-
- 1:30** **Summary of Written Public Comments**
Karen Mowrer, Ph.D.
Health Science Policy Analyst
OARC, NIMH
-
- 1:40** **Request for Public Comment**
Susan Daniels, Ph.D.
Director, OARC and Executive Secretary,
IACC
-
- 1:45** **IACC Committee Member Discussion of**
Public Comments

Meeting of the IACC

Summary of Written Public Comments

Karen Mowrer, Ph.D.

Health Science Policy Analyst

Office of Autism Research Coordination, NIMH

Meeting of the IACC

Request for Public Comments on IACC Strategic Plan

Susan Daniels, Ph.D.

Director, Office of Autism Research Coordination, NIMH
Executive Secretary, IACC

2016 IACC Strategic Plan Request for Public Comment

Susan A. Daniels, Ph.D.

Director, Office of Autism Research Coordination

Executive Secretary, IACC

National Institute of Mental Health

IACC Full Committee Meeting

October 26, 2016

2016 IACC Strategic Plan Request for Public Comment

- On behalf of the IACC, OARC issued a Federal Register Notice soliciting public comment on the research, service, and policy priorities for the topics addressed by the current strategic plan:
 - Q1 Diagnosis and Screening
 - Q2 Underlying Biology
 - Q3 Risk Factors
 - Q4 Treatments & Interventions
 - Q5 Services
 - Q6 Lifespan
 - Q7 Research Infrastructure and Surveillance
- Comments were provided to Strategic Plan Working Groups and all comments are now publicly available on the IACC website
- Within each question comments are grouped by themes addressed
- **Over 1,100 comments were received**

Respondent Categories

- **Parents and family members**
- **Service providers**
- **Researchers**
- **Advocates/Professional Societies**
- **Educators**
- **Medical/Therapy Practitioners**
- **Family Assistance/Navigation**
- **Self advocates**
- **Research trainees**
- **Government employees**
- **International**

Question 1: Diagnosis & Screening

- Need better recognition and diagnosis of subgroups
- Need better understanding of early signs and symptoms
- Families need emotional support following diagnosis and assistance in navigating access to services
- Improve accuracy and awareness of diagnosis in females/address sex and gender disparities in diagnosis
- Improvements in the accuracy and usability of screening and diagnosis tools
- Need more and increased access to genetic screening
- Need greater research and identification of biomarkers, and use of these biomarkers in screening and diagnosis
- Need improvements in access and accuracy of adult and adolescent diagnosis
- Need to address the multifaceted disparities in diagnosis across racial, cultural, socioeconomic, and regional lines
- Need to increase/decrease early screening and diagnosis of ASD in children
- Need to reduce the time to diagnosis by improving service access and diagnostic tools/process
- Need to strengthen link between initial diagnosis and access to services and interventions
- Parents and caregivers need greater education so that they can recognize signs and symptoms
- Practitioners need to listen to and consider parent concerns about early signs and symptoms
- Universal screening for ASD is needed
- Workforce development, including access to qualified practitioners and improvements in the training of the existing workforce
- Current priorities are appropriate (diagnosis and screening tools, early signs, symptoms and biomarkers, identification of subgroups, disparities in diagnosis)

Question 2: Underlying Biology

- Need further research on the genetics of autism, and genetic tests should be more accessible
- Need more developmental biology research
- Need more research and a better understanding of genetic syndromes related to ASD
- Need more research and better understanding of the biomarkers and symptoms of ASD, and the heterogeneity of symptoms
- Need more research into the contribution of immune and metabolic pathways to autism
- Need more research on cognitive and behavioral biology
- Need more research on the basic neuroscience of ASD
- Need more research on the biology and relationship of co-occurring conditions in ASD
- Need more research on the molecular biology of ASD
- Need more research on sex and gender differences, inclusive of both biological sex and self-identified gender
- Need research to better understand, differentiate, and treat subgroups of people with autism
- Need more research to better understand sensory processing and motor function in ASD
- Need more translational and interdisciplinary research to improve the lives of people with ASD
- Need to prioritize gut-brain interaction research
- Current priorities are appropriate (molecular biology and neuroscience, developmental biology, cognitive and behavioral biology, genetic syndromes related to ASD, sex differences, immune and metabolic aspects, and co-occurring conditions in ASD)
- Understanding the biology of ASD is not a priority, relative to other areas (i.e. treatment and services)

Question 3: Risk Factors

- Need better methods for testing contributions of risk factors from multiple domains to better understand risk of autism
- Need more research into better understanding of environmental risk factors, defined broadly to including both chemical and social environments
- Need more research on epigenetic risk factors
- Need more research on genetic risk factors
- Need more research on immune and metabolic risk factors
- Need more research on maternal and prenatal factors
- Need more research on the interaction of genetic and environmental factors
- Need more research on the risk factors for co-occurring conditions in autism
- Need more research on the role of the microbiome and gastrointestinal risk factors
- Need more research to better understand heritability and risk of autism in families
- Need more research to understand the role of vaccines in causing autism
- Need less/no additional research on the role of vaccines in autism
- Current priorities are appropriate (genetic and environmental risk factors, gene-environment interactions, and the potential role of epigenetics and the microbiome)
- The cause and prevention of autism are not a priority, either because resources can be better used in other areas or because preventing autism should not be a goal

Question 4: Treatments & Interventions (385 responses rec'd as of 6/29)

- Need a qualified workforce trained in providing treatments and interventions ; need both a greater number and improved training of current clinicians, therapists, and school employees
- Need to prioritize early intervention
- Need to educate parents about available treatments and interventions, and to help provide these interventions
- Endorsement of specialized or ASD specific treatments and interventions
- Improve availability and efficacy of treatments and interventions specifically for adult and adolescents with ASD
- Improve efficacy and availability of behavioral treatments and interventions
- Improve efficacy and availability of interventions in educational settings
- Improve the evidence base for treatments and interventions, and make that information more readily available and widely used
- Personalized combinations and types of treatments and interventions will be the most efficacious
- Positive and negative comments about searching for a “cure” rather than treatments or interventions
- Research and availability of technology based or assistive technology treatments and interventions
- Research and availability of treatments and interventions for co-occurring conditions
- Need research on biomedical and pharmacological treatments and interventions to improve efficacy and reduce side effects
- Need research on the efficacy and availability of complementary, alternative or integrative treatments and interventions
- Need research on long term outcomes of treatments and intervention, as well as the translation and implementation of research based treatments and interventions
- Improve coordination of treatments and interventions between services and practitioners
- Current priorities are appropriate (behavioral, medical/pharmacologic, educational, technology-based, and complementary/integrative interventions)

These slides do not reflect decisions of the IACC and are for discussion purposes only.

Question 5: Services

(467

responses rec'd as of 6/29)

- Access to early intervention services is a priority
- Disparities in access to services should be addressed
- Families need access to services to reduce the mental and emotional burden of caring for those with ASD
- Improve the efficacy and cost effectiveness of services and service delivery
- Improve the quality and availability of services within the educational systems
- Improve the service systems and service models
- Increase the accessibility and utilization of services.
- Need better coordination between service providers, taking into account what is relevant for the individual and the choices of those with ASD and their families/caregivers
- Need for an adequately trained and compensated workforce to improve available services and service delivery
- Need for better services to foster community inclusion of those with ASD
- Need to be more and better access to specialized services for ASD
- Parents/caregivers need assistance navigating complicated service systems.
- Prioritize services to improve the health and safety, including addressing interactions with law enforcement and wandering
- The broader community needs to be better educated about ASD, to lead to better understanding and inclusion
- The cost of services is prohibitive, and research and policies are needed to reduce these barriers to access
- Current priorities are appropriate (service access and utilization, service systems, education, family well-being, efficacious and cost-effective service delivery, health and safety issues affecting children, and community inclusion)

- Focus on the treatment or cause of autism rather than the delivery of services

These slides do not reflect decisions of the IACC and are for discussion purposes only.

Question 6: Lifespan

- Improve access to and quality of adult services, including additional research to improve evidence based services for adults
- Improve access to diagnosis for adolescents and adults
- Improve community integration/inclusion, including social isolation and community education about ASD
- Improve the quality, accessibility of housing options
- Improve transition services, and provide better assistance for young adults and their families during transitions
- Long term and financial planning are a priority for research, services, and policy
- Need assistance for adults with autism and their families in navigating available adult services
- Need for a larger, better trained and compensated workforce for adults with ASD
- Research and services to improve health, medical care, safety and quality of life across the lifespan
- Research, services and policies are needed to improve vocational/employment and post-secondary education opportunities
- Services and research should take into account the perspective and choices of adults and their families/caregivers
- Current priorities are all important/relevant (health and quality of life across the lifespan, aging, transition, and adult services, including education, vocational training, employment, housing, financial planning and community integration.)
- Focus should be on early intervention or developing effective treatments; adults/lifespan are not a research priority
- Improve caregiver support

Question 7: Research Infrastructure and Surveillance

- Improve services infrastructure
- Increase collaboration and coordination among services providers
- Increase collaboration and coordination of research including interdisciplinary research
- Increase the dissemination of research, and the translation of research into practice
- Need greater development of the research workforce
- Need more and improved surveillance of ASD prevalence, including by race/ethnicity, gender and age
- Need research infrastructure, i.e. databases, research and clinical trial policies
- Research should include the voices and participation of individuals with autism and their families
- Current priorities are appropriate/important (research infrastructure needs, ASD surveillance research, research workforce development, dissemination of research information, and strengthening collaboration)
- Prioritize services and interventions rather than research

Question 7: Research Infrastructure and Surveillance

- Improve services infrastructure
- Increase collaboration and coordination among services providers
- Increase collaboration and coordination of research including interdisciplinary research
- Increase the dissemination of research, and the translation of research into practice
- Need greater development of the research workforce
- Need more and improved surveillance of ASD prevalence, including by race/ethnicity, gender and age
- Need research infrastructure, i.e. databases, research and clinical trial policies
- Research should include the voices and participation of individuals with autism and their families
- Current priorities are appropriate/important (research infrastructure needs, ASD surveillance research, research workforce development, dissemination of research information, and strengthening collaboration)
- Prioritize services and interventions rather than research

Meeting of the IACC

IACC Committee Member Discussion of Public Comments

Meeting of the IACC

Discussion of Nominated 2016 Science Advances

2016 Summary of Advances Nominations

July - October

Q1. When should I be concerned?

No articles were nominated in July - October 2016 for Question 1

Q2. How can I understand what is happening?

Molecular Psychiatry

July 5, 2016

Altered proliferation and networks in neural cells derived from idiopathic autistic individuals

Marchetto MC, Belinson H, Tian Y, Freitas BC, Fu C, Vadodaria KC, Beltrao-Braga PC, Trujillo CA, Mendes AP, Padmanabhan K, Nunez Y, Ou J, Ghosh H, Wright R, Brennand KJ, Pierce K, Eichenfield L, Pramparo T, Eyler LT, Barnes CC, Courchesne E, Geschwind DH, Gage FH, Wynshaw-Boris A, Muotri AR

Journal of the American Academy of **CHILD & ADOLESCENT PSYCHIATRY**

July 2016

Salience Network Connectivity in Autism Is Related to Brain and Behavioral Markers of Sensory Overresponsivity

Green SA, Hernandez L, Bookheimer SY, Dapretto M

Q2. How can I understand what is happening?



December 2016

Infants' observation of tool-use events over the first year of life

Libertus K, Greif ML, Needham AW, Pelphrey K



September 2016

Functional Connectivity of the Amygdala Is Disrupted in Preschool-Aged Children With Autism Spectrum Disorder

Shen MD, Li DD, Keown CL, Lee A, Johnson RT, Angkustsiri K, Rogers SJ, Müller RA, Amaral DG, Nordahl CW

Q3. What caused this to happen and can it be prevented?

American Journal of
EPIDEMIOLOGY

February 1, 2016

Maternal Consumption of Seafood in Pregnancy and Child Neuropsychological Development: A Longitudinal Study Based on a Population With High Consumption Levels

Julvez J, Méndez M, Fernandez-Barres S, Romaguera D, Vioque J, Llop S, Ibarluzea J, Guxens M, Avella-Garcia C, Tardón A, Riaño I, Andiaarena A, Robinson O, Arijia V, Esnaola M, Ballester F, Sunyer J

ehp ENVIRONMENTAL
HEALTH
PERSPECTIVES

July 1, 2016

Project TENDR: Targeting Environmental Neuro-Developmental Risks. The TENDR Consensus Statement

Bennett D, Bellinger DC, Birnbaum LS, Bradman A, Chen A, Cory-Slechta DA, Engel SM, Fallin MD, Halladay A, Hauser R, Hertz-Picciotto I, Kwiatkowski CF, Lanphear BP, Marquez E, Marty M, McPartland J, Newschaffer CJ, Payne-Sturges D, Patisaul HB, Perera FP, Ritz B, Sass J, Schantz SL, Webster TF, Whyatt RM, Woodruff TJ, Zoeller RT, Anderko L, Campbell C, Conry JA, DeNicola N, Gould RM, Hirtz D, Huffling K, Landrigan PJ, Lavin A, Miller M, Mitchell MA, Rubin L, Schettler T, Tran HL, Acosta A, Brody C, Miller E, Miller P, Swanson M, Witherspoon NO; American College of Obstetricians and Gynecologists (ACOG); Child Neurology Society; Endocrine Society; International Neurotoxicology Association; International Society for Children's Health and the Environment; International Society for Environmental Epidemiology; National Council of Asian Pacific Islander Physicians; National Hispanic Medical Association; National Medical Association

Q3. What caused this to happen and can it be prevented?

International Journal of
Epidemiology

June 28, 2016

Acetaminophen use in pregnancy and neurodevelopment: attention function and autism spectrum symptoms

Avella-Garcia CB, Julvez J, Fortuny J, Rebordosa C, García-Esteban R, Galán IR, Tardón A, Rodríguez-Bernal CL, Iñiguez C, Andiarena A, Santa-Marina L, Sunyer J

Q4. Which treatments and interventions will help?

Research in Autism Spectrum Disorders

July 2016

The effects of embodied rhythm and robotic interventions on the spontaneous and responsive social attention patterns of children with Autism Spectrum Disorder (ASD): A pilot randomized controlled trial

Srinivasan SM, Eigsti IM, Neelly L, Bhat AN



July-August 2016

Longitudinal Effects of Adaptive Interventions With a Speech-Generating Device in Minimally Verbal Children With ASD

Almirall D, DiStefano C, Chang YC, Shire S, Kaiser A, Lu X, Nahum-Shani I, Landa R, Mathy P, Kasari C

The International Journal of Research and Practice • Volume 18 Number 1 January 2014



August 2016

Social network analysis of children with autism spectrum disorder: Predictors of fragmentation and connectivity in elementary school classrooms

Anderson A, Locke J, Kretzmann M, Kasari C; AIR-B Network

Q5. Where can I turn for services?

No articles were nominated in July - October 2016 for Question 5

Q6. What does the future hold, particularly for adults?

No articles were nominated in July - October 2016 for Question 6

Q7. What other infrastructure and surveillance needs must be met?

No articles were nominated in July - October 2016 for Question 7

IACC Summary of Advances

Susan A. Daniels, Ph.D.

Director, Office of Autism Research Coordination

Executive Secretary, IACC

National Institute of Mental Health

IACC Full Committee Meeting

October 26, 2016

2016 Summary of Advances Process

- **The committee has been receiving quarterly data calls for submission of nominations**
- **Submitted nominations are discussed at each meeting; nominations require a written justification**
- **Issues:**
 - **Few nominations received; some Question areas not covered well**
 - **Will those areas be covered in the final data call in December?**
 - **All nominations do not have a justification; do we want to keep that requirement?**

2016 Summary of Advances Process

End of year process:

- **Final nominations for 2016 submitted in December; discussed in January (if large number of submissions, we can either set aside more time for discussion or not discuss all nominations)**
- **Then committee voting process to select top 20 advances? Or certain number of advances per Question to ensure coverage of all questions?**
- **OARC to provided short, lay-friendly summaries of the selected articles, as previously?**

Meeting of the IACC

Break

Meeting of the IACC

Afternoon Agenda - continued

2:45 Panel on Autism in Women and Girls

2:45 Introduction

Kevin Pelphrey, Ph.D.

IACC Member and Panel Chair

Director, Autism and Neurodevelopmental
Disorders Institute

George Washington University and
Children's National Medical Center

2:50 Somer Bishop, Ph.D.

Assistant Professor

University of California, San Francisco

Meeting of the IACC

Afternoon Agenda - continued

3:10 The Autism Sisters Project

Alison Singer, M.B.A.

IACC Member

President, Autism Science Foundation

3:20 The Role of Genetics and Sex-Differential Biology in Risk for Autism

Donna Werling, Ph.D.

Postdoctoral Scholar, Department of Psychiatry
University of California San Francisco School of
Medicine



Phenotypic differences between males and females with autism spectrum disorders (ASD)

Somer L. Bishop, PhD

Department of Psychiatry and Weill Institute for Neurosciences

University of California, San Francisco

10/26/2016

Outline

- State of current knowledge
 - Discrepant findings
 - Methodological limitations

Outline

- State of current knowledge
 - Discrepant findings
 - Methodological limitations
- (CONFUSED)

Outline

- State of current knowledge
 - Discrepant findings
 - Methodological limitations
- Moving forward
 - Donna, Kevin, and Alison


Outline

- State of current knowledge
 - Discrepant findings
 - Methodological limitations
- Moving forward
 - Alison, Donna, and Kevin

(HOPEFUL FOR THE FUTURE!)

Mix of consistencies and inconsistencies


- More males with ASD than females
 - Many changes in epidemiological trends, but preponderance of males remains (though ratio varies across samples)
- Relative to overall sex ratio in ASD, females are over-represented at the lower end of the IQ continuum and under-represented at the higher end



Autism and Developmental Disabilities Monitoring Network Surveillance Year Principal, I. & Centers for Disease Control and, P. Prevalence of autism spectrum disorders--Autism and Developmental Disabilities Monitoring Network, 14 sites, United States, 2008. *Morbidity and mortality weekly report. Surveillance summaries (Washington, D.C. : 2002)* **61**, 1-19 (2012).


Nonverbal IQ: Simons Simplex Collection

SSC Males



Mean =86.22
Std. Dev. =25.426
N =1,907

SSC Females



Mean =77.91
Std. Dev. =25.235
N =299

Mix of consistencies and inconsistencies

- More males with ASD than females
 - Many changes in epidemiological trends, but preponderance of males remains (though ratio varies across samples)
- Relative to overall sex ratio in ASD, females are over-represented at the lower end of the IQ continuum and under-represented at the higher end
- Longstanding interest in examining sex differences
 - Discrepant findings related to phenotype

Social-communication

- Similar levels of ASD symptoms (Lord et al., 1982)
- Toddler/preschool boys had higher language, motor and social-competence (Carter et al., 2007)
- Preschool girls had fewer social-communication impairments (Zwaigenbaum et al., 2012)
- Adult females had fewer social-communication difficulties (Lai et al., 2011)
- Girls had fewer teacher-reported behavior problems (Mandy et al., 2012)

Restricted and repetitive behaviors

- Females exhibited lower repetitive behavior scores (e.g., Hartley et al., 2009; Mandy et al., 2011; Frazier et al., 2014)
 - Seen across multiple measures (3Di, ADI-R, RBS-R, ADOS)
- No sex differences in community-based sample of 288 toddlers with ASD (54 girls) (Reinhardt et al, 2014)

Questions persist


- Clinicians and researchers continue to wonder (and worry) about sex differences in behavioral manifestations of ASD

Clinician perceptions

<i>Gender</i>	Female: 86% (n=91)	Male: 14% (n=15)		
<i>Involvement in dx</i>	57% make dx (n=58)	31% perform assessments (n=32)	12% participate in evaluation (n=12)	
<i>Years experience</i>	58% have 10+ years (n=56)	26% have spent 6-9 years (n=25)	13% have 1-5 years experience (n=12)	3 % have less than one year (n=3)
<i>Primary age range seen</i>	7% see mostly adults (n=7)	9% see primarily adolescents (n=8)	37% work with school age children (n=35)	47% see children 5 years old or younger (n=44)
<i>Number seen per month</i>	Mean = 15.8 people, median = 8			
<i>Number of females seen per month</i>	Mean = 3.4 females, median =2			


Jamison, Huerta, Bishop, & Halladay (under review).

Observed differences in core and associated symptoms




Jamison, Huerta, Bishop, & Halladay (under review).

Observed differences in social-communication



Jamison, Huerta, Bishop, & Halladay (under review).

Observed differences in RRBs



Jamison, Huerta, Bishop, & Halladay (under review).


Clinical observations vs. empirical data

- Why the mismatch?
 - Measurement issues
 - Sampling issues
 - Methodological issues

Measurement issues


- Existing measures may lack sensitivity for detecting some females with ASD
 - Diagnostic constructs (which in turn are reflected on measures) could be sex-biased
- Scores on ASD measures are affected by individual factors like IQ and emotional/behavioral problems (EBP)

ADI-R scores by diagnostic group and level of EBP



Havdahl, Hus Bal, Huerta, Pickles, Oyen, Stoltenberg, Lord, & Bishop (in press). Multidimensional influences on autism symptom measures: Implications for use in etiological research. *Journal of the American Academy of Child and Adolescent Psychiatry*.

SRS scores by diagnostic group and level of EBP




Havdahl, Hus Bal, Huerta, Pickles, Oyen, Stoltenberg, Lord, & Bishop (in press). Multidimensional influences on autism symptom measures: Implications for use in etiological research. *Journal of the American Academy of Child and Adolescent Psychiatry*.

Sampling Issues

- Measurement issues can affect ascertainment
 - Over-reliance on standardized screening or diagnostic measures could skew samples (e.g., toward girls with lower IQ and/or more behavior problems)

Referral bias

Mean T scores in preschoolers with ASD (N=102) and non-ASD diagnoses (N=57)



Havdahl, K. A., von Tetzchner, S., Huerta, M., Lord, C., & Bishop, S. L. (2016). Utility of the Child Behavior Checklist as a Screener for Autism Spectrum Disorder. *Autism Research*, 9(1), 33-42. doi:10.1002/aur.1515

Sampling Issues


- Measurement issues can affect ascertainment
 - Over-reliance on standardized screening or diagnostic measures could skew samples (e.g., toward girls with lower IQ and/or more behavior problems)
- Small clinical samples
 - Ns for females are particularly small
 - May not be powered to properly account for other important individual differences

School-aged/adolescent; verbally fluent

	Male	Female
Number of Participants	396	85
Age in years, <i>M (SD)</i>	8.9 (2.9)	8.7 (2.8)
VIQ, <i>M (SD)</i>	99.6 (18.9)	104.6 (16.7)
NVIQ, <i>M (SD)</i>	104.7 (15.5)	104.3 (14.8)

Bishop, Sweeney, Huerta, Havdahl, & Lord (unpublished).

ADOS-2 Module 3 ASD classification



Bishop, Sweeney, Huerta, Havdahl, & Lord (unpublished).

Calibrated severity scores (CSS)


- Controlling for VIQ and age, sex significantly predicted:
 - Overall CSS ($B = -.57$, CI 95% -1.08 to -0.06, $p = .03$)
 - RRB Domain Calibrated Scores ($B = -.89$, CI 95% -1.4 to -.34, $p = .002$)
- In this sample, even females with lower scores (including those who scored below instrument cut-offs) still received best-estimate clinical diagnoses of ASD

Bishop, Sweeney, Huerta, Havdahl, & Lord (unpublished).

Methodological issues


- Detecting meaningful differences relies on identification of appropriate comparison groups
 - Who is a *relevant* control? (e.g., IQ/age matched males with ASD vs. IQ/age matched non-ASD female?)
- Clear need for longitudinal data

Employment/PSE at the First Time Point after High School Exit




Taylor, J. L., Henninger, N. A., & Mailick, M. R. (2015). Longitudinal patterns of employment and postsecondary education for adults with autism and average-range IQ. *Autism, 19*(7), 785-793. doi:10.1177/1362361315585643

Patterns of Employment/PSE over Time



Taylor, J. L., Henninger, N. A., & Mailick, M. R. (2015). Longitudinal patterns of employment and postsecondary education for adults with autism and average-range IQ. *Autism*, 19(7), 785-793. doi:10.1177/1362361315585643

Men vs. women with ID



Taylor, J. L., & Mailick, M. R. (2014). A longitudinal examination of 10-year change in vocational and educational activities for adults with autism spectrum disorders. *Developmental Psychology*, 50(3), 699-708.
doi:10.1037/a0034297

Methodological issues

- Detecting meaningful differences relies on identification of appropriate comparison groups
 - Who is a *relevant* control? (e.g., IQ/age matched males with ASD vs. IQ/age matched non-ASD female?)
- Clear need for longitudinal data
- Need to move existing behavioral measures
- Incorporate different measurement strategies

Conclusions

- There do appear to be at least subtle sex differences in phenotype within certain groups
 - Ascertainment and measurement issues present major challenges
- Sex is one stratification variable worth considering, but it needs to be considered in the context of other behavioral and biological variables that we know are important

Thank you

- **UMACC/CADB**
families, clinicians and
researchers
- Alycia Halladay
- Alexandra Havdahl
- Marisela Huerta
- Rene Jamison
- Catherine Lord
- Shanping Qiu
- Michael Sweeney
- Julie Taylor

EXTRA SLIDES

Direction of Clinician Responses: Early Childhood

Criteria / Severity	Less Severe (M<F)	Similar (M=F)	More Severe (F>M)
Social reciprocity	33% (n=22)	62% (n=41)	5% (n=3)
Nonverbal behaviors	33% (n=22)	60% (n=39)	6% (n=4)
Developing, maintaining relationships	23% (n=15)	71% (n=46)	6% (n=4)
Stereotyped/Repetitive Behaviors	32% (n=21)	65% (n=43)	3% (n=2)
Insistence on Sameness	24% (n=16)	71% (n=47)	5% (n=3)
Restricted/Fixated Interests	33% (n=22)	65% (n=43)	2% (n=1)
Hyperreactivity to sensory	9% (n=6)	86% (n=55)	5% (n=3)
Hyporeactivity to sensory	17% (n=11)	67% (n=43)	16% (n=10)

Jamison, Huerta, Bishop, & Halladay (under review).

Direction of Clinician Responses: School Age

Criteria / Severity	Less Severe (M<F)	Similar (M=F)	More Severe (F>M)
Social reciprocity	48% (n=30)	48% (n=30)	3% (n=2)
Nonverbal behaviors	44% (n=27)	54% (n=33)	2% (n=1)
Developing, maintaining relationships	25% (n=15)	70% (n=43)	5% (n=3)
Stereotyped/Repetitive Behaviors	55% (n=34)	40% (n=25)	5% (n=3)
Insistence on Sameness	23% (n=14)	73% (n=45)	5% (n=3)
Restricted / Fixated Interests	38% (n=23)	59% (n=36)	3% (n=2)
Hyper-reactivity to Sensory	8% (n=5)	85% (n=52)	5% (n=3)
Hypo-reactivity to Sensory	19% (n=11)	76% (n=43)	7% (n=4)

Jamison, Huerta, Bishop, & Halladay (under review).

Direction of Clinician Responses: Adolescence

Criteria / Severity	Less Severe (M<F)	Similar (M=F)	More Severe (F>M)
Social reciprocity	37% (n=23)	55% (n=34)	8% (n=3)
Nonverbal behaviors	41% (n=25)	56% (n=34)	3% (n=2)
Developing, maintaining relationships	16% (n=10)	69% (n=42)	15% (n=9)
Stereotyped/Repetitive Behaviors	47% (n=29)	48% (n=30)	5% (n=3)
Insistence on Sameness	21% (n=13)	71% (n=44)	8% (n=5)
Restricted / Fixated Interests	31% (n=19)	63% (n=39)	6% (n=4)
Hyper-reactivity to Sensory	8% (n=5)	87% (n=52)	5% (n=3)
Hypo-reactivity to Sensory	23% (n=14)	74% (n=45)	3% (n=2)


Jamison, Huerta, Bishop, & Halladay (under review).

Direction of Clinician Responses: Adult

Criteria / Severity	Less Severe (M<F)	Similar (M=F)	More Severe (F>M)
Reciprocity	31% (n=17)	59% (n=32)	9% (n=5)
Nonverbal behaviors	41% (n=22)	52% (n=28)	7% (n=4)
Developing, maintaining relationships	17% (n=9)	74% (n=39)	9% (n=5)
Stereotyped/Repetitive Behaviors	36% (n=19)	64% (n=34)	0% (n=0)
Insistence on Sameness	19% (n=10)	78% (n=42)	4% (n=2)
Restricted / Fixated Interests	22% (n=12)	76% (n=41)	2% (n=1)
Hyper-reactivity to Sensory	8% (n=4)	87% (n=45)	6% (n=3)
Hypo-reactivity to Sensory	13% (n=7)	80% (n=43)	7% (n=4)


Jamison, Huerta, Bishop, & Halladay (under review).

ADOS items showing significant score discrepancies by sex



Bishop, Sweeney, Huerta, Havdahl, & Lord, (unpublished).

ADOS scores by diagnostic group and level of EBP



Havdahl, Hus Bal, Huerta, Pickles, Oyen, Stoltenberg, Lord, & Bishop (in press). Multidimensional influences on autism symptom measures: Implications for use in etiological research. *Journal of the American Academy of Child and Adolescent Psychiatry*.

- Listening to our Daughters: Girls & Women with Autism will Inform Novel Treatments

Kevin Pelphrey

*Carbonell Family Professor and Director
Autism and Neurodevelopmental Disorders Institute*


October 26, 2016

THE GEORGE
WASHINGTON
UNIVERSITY

WASHINGTON, DC




Brain Systems for Social Cognition




Pelphrey et al. (2003) *Journal of Neuroscience*

Can we see autism's signature in the
individual brain?

Classification Analysis




A weak response to biological motion is a marker of autism in boys (but not girls!)



Björnsdotter et al., *JAMA: Psychiatry*, 2016

Autism Center of Excellence: Girls Network





THE GEORGE
WASHINGTON
UNIVERSITY
WASHINGTON, DC



Milestones	April 1 2016
Target: Total Recruitment	374
Actual: Total Recruitment	454
Actual/Target Ratio: Total Recruitment	121%
Target: Racial Minority Recruitment	65
Actual: Racial Minority Recruitment	110
Actual/Target Ratio: Racial Minority Recruitment	169%
Target: Hispanic Ethnicity Recruitment	33
Actual: Hispanic Ethnicity Recruitment	60
Actual/Target Ratio: Hispanic Ethnicity Recruitment	182%


Sex differences in brain response to coherent versus scrambled biological motion


ASD ♀ > ASD ♂



♀:female; ♂:male; dmPFC:dorsomedial prefrontal cortex; FFG:fusiform gyrus; ITG:inferior temporal gyrus; pSTS:posterior superior temporal sulcus vmPFC: ventromedial prefrontal cortex

ASD ♀ > ASD ♂





Girls



Boys



How do we translate basic
science into practicable
treatments aimed at *target
engagement?*



IMPRECISION MEDICINE

For every person they do help (blue), the ten highest-grossing drugs in the United States fail to improve the conditions of between 3 and 24 people (red).

1. ABILIFY (aripiprazole) Schizophrenia



2. NEXIUM (esomeprazole) Heartburn




3. HUMIRA (adalimumab) Arthritis



4. CRESTOR (rosuvastatin) High cholesterol



5. CYMBALTA (duloxetine) Depression



6. ADVAIR DISKUS (fluticasone propionate) Asthma



7. ENBREL (etanercept) Psoriasis



8. REMICADE (infliximab) Crohn's disease



9. COPAXONE (glatiramer acetate) Multiple sclerosis



10. NEULASTA (pegfilgrastim) Neutropenia




Based on published number needed to treat (NNT) figures. For a full list of references, see Supplementary Information at go.nature.com/4dr78E.

Schork (2015) *Nature*



Pivotal Response Training (PRT)




Change in Behavior: Social Responsiveness Scale (SRS)



Neuro-prediction of treatment response




Yang et al. (in press)
Nature: Translational Psychiatry




p 
 .01 .0001


Change in brain,
 driving change in
 behavior



Yang et al. (in press)
Nature: Translational Psychiatry




MASD > F ASD




FASD > MASD


Total SRS Change - PRT vs. Waitlist Comparison



Vineland - Socialization Change: PRT vs. Waitlist




Can we boost brain responses before treatment, to make treatment work



Art by Charlotte Pretzsch

Intranasal Oxytocin – Social Judgments




Gordon et al. (2013) *Proceedings of the National Academy of Sciences*

Linking neural
signatures, genes,
and behavior in to
shape
developmental
trajectories




Results: fNIRS (LR and HR 3-Month-Old Infants)

LEFT



RIGHT



Acknowledgments

The Carbonell Family

NIMH

NICHD

NINDS

Simons Foundation

Autism Speaks

Hilibrand Foundation

John Merck Scholars Fund

Autism Science Foundation

I thank the participants and their families for participating in our research.

I thank my colleagues who make this work so much fun.

kevinpelphey@gwu.edu


The role of genetics and sex-differential biology in risk for autism

Donna Werling, PhD
Sanders & State Labs, UCSF
October 26, 2016




Autism prevalence is sex-biased

- ~4:1 males:females have a diagnosis of autism spectrum disorder (ASD)



Autism prevalence is sex-biased


- ~4:1 males:females have a diagnosis of autism spectrum disorder (ASD)¹
- 8 males and 3 females in the 11 cases originally reported by Leo Kanner, 1943²
- Male bias consistent over time and across countries¹




¹Fombonne, 2009, *Pediatr Res*. ²Kanner, 1943, *Nervous Child*.

Why study sex bias in ASD from a biological perspective?

Sex appears to be a potent modulator of ASD risk




Males: 1 in 42 diagnosed




Females: 1 in 189 diagnosed

Why study sex bias in ASD from a biological perspective?

Sex appears to be a potent modulator of ASD risk





Males: 1 in 42 diagnosed




Females: 1 in 189 diagnosed

Why study sex bias in ASD from a biological perspective?


Sex appears to be a potent modulator of ASD risk




Female Protective Effect (FPE) Model for ASD = Liability model




Female Protective Effect (FPE) Model for ASD = Liability model




Female Protective Effect (FPE) Model for ASD = *Multiple threshold* liability model




Female Protective Effect (FPE) Model for ASD = *Multiple threshold* liability model





FPE model predicts that diagnosed females carry greater risk than males





FPE model predicts that diagnosed females carry greater risk than males





FPE model predicts that diagnosed females carry greater risk than males




FPE model predicts that diagnosed females carry greater risk than males




FPE model predicts that diagnosed females carry greater risk than males




Higher incidence of disruptive, *de novo* variants in ASD females




Copy number variants (CNVs)¹



Insertion/Deletions (Indels)²





Single nucleotide variants (SNVs)³




¹Sanders et al, 2015, *Neuron*. ²Dong et al, 2014, *Cell Rep*. ³De Rubeis et al, 2014, *Nature*.

Siblings of female cases have higher ASD traits than siblings of male cases




Siblings of female cases have higher ASD traits than siblings of male cases



Autistic traits in siblings?


Mean sex-and-zygosity-normed Z scores

Increase in risk to siblings of female probands




	TEDS	CATSS
■ Siblings of All Non-Probands N(TEDS) = 3,444 N(CATSS) = 5,340	-0.06 (p<0.0001 *§)	-0.05 (p<0.0001 *§)
■ Siblings of Male Probands N(TEDS) = 262 N(CATSS) = 470	0.42 (p=0.002 §)	0.34 (p=0.02 §)
■ Siblings of Female Probands N(TEDS) = 136 N(CATSS) = 230	0.78	0.55

FPE model predicts that females respond differently to liability that is sufficient for diagnosis in males



FPE model predicts that females respond differently to liability that is sufficient for diagnosis in males




1. Quantitative:

Females are protected and have neurotypical phenotype.

2. Qualitative:

Females present symptoms differently than males, and are not diagnosed.

FPE model predicts that females respond differently to liability that is sufficient for diagnosis in males



Hypothesis:

Sex-differential biology contributes to male and female differences in ASD risk and/or symptom presentation

1. Quantitative:


Females are protected and have neurotypical phenotype.

2. Qualitative:


Females present symptoms differently than males, and are not diagnosed.

We can use gene expression analysis to identify sex differences that contribute to the FPE

1. Identify genes with sex-differential expression levels in the human brain



2. Characterize the relationship between sex-DEX genes and ASD biology




BRAINSPAN

ATLAS OF THE DEVELOPING HUMAN BRAIN


Table 1 | Periods of human development and adulthood as d in this study

Period	Description	Age
1	Embryonic	4 PCW \leq Age < 8 PCW
2	Early fetal	8 PCW \leq Age < 10 PCW
3	Early fetal	10 PCW \leq Age < 13 PCW
4	Early mid-fetal	13 PCW \leq Age < 16 PCW
5	Early mid-fetal	16 PCW \leq Age < 19 PCW
6	Late mid-fetal	19 PCW \leq Age < 24 PCW
7	Late fetal	24 PCW \leq Age < 38 PCW
8	Neonatal and early infancy	0 M (birth) \leq Age < 6 M
9	Late infancy	6 M \leq Age < 12 M
10	Early childhood	1 Y \leq Age < 6 Y
11	Middle and late childhood	6 Y \leq Age < 12 Y
12	Adolescence	12 Y \leq Age < 20 Y
13	Young adulthood	20 Y \leq Age < 40 Y
14	Middle adulthood	40 Y \leq Age < 60 Y
15	Late adulthood	60 Y \leq Age


M, postnatal months; PCW, post-conceptional weeks; Y, postnatal years.



There is no evidence of an autosomal gene with XY levels of sexual dimorphism in the brain




There is no evidence of an autosomal gene with XY levels of sexual dimorphism in the brain




Sex-DEX genes identified by permutation approach ($Q \leq 0.05$; top-ranking sex-DEX in ≥ 2 consecutive developmental periods from same brain region):


- Higher expression in males:
 - 505 protein-coding genes, 129 noncoding transcripts
- Higher expression in females:
 - 442 protein-coding genes, 466 noncoding transcripts




Sex-DEX genes are not enriched for neuronal markers




Male-DEX genes show enrichment for microglial and endothelial cell markers




Male-DEX genes show enrichment for microglial and endothelial cell markers




Male-DEX genes show enrichment for microglial and endothelial cell markers




We observe a relationship between sex-DEX genes and ASD biology




We observe a relationship between sex-DEX genes and ASD biology




Enrichment evidence suggests a male sensitization model of ASD risk




Enrichment evidence suggests a male sensitization model of ASD risk



Enrichment evidence suggests a male sensitization model of ASD risk



Enrichment evidence suggests a male sensitization model of ASD risk



Summary

- Intersection of ASD neurobiology and sex-differential neurobiology provides an approach to understand sex bias
- Male-biased expression:
 - Microglial genes
 - Collagen genes and endothelial cell markers
 - Glial genes dysregulated in ASD brain, suggesting a male-sensitization effect
- Validation in independent samples is needed
 - Results are preliminary and based on analysis of a single data set


Looking forward

- Well powered, foundational data sets comparing males and females will be required for:
 - Rigorous validation of sex-differential patterns
 - Thorough investigation of relationships between sex-differential and ASD biology

Data types

- RNA sequencing for gene expression
- ChIP-seq for identifying gene targets of the estrogen and androgen receptors

2x2 design



Developmental stages

- Fetal
- Perinatal
- Early postnatal/childhood
- Puberty
- Adulthood

Cell types

- Neurons
- Microglia
- Astrocytes

Brain regions

- Neocortex
- Thalamus
- Striatum
- Cerebellum

Organisms

- Human
- Primate
- Mouse


The role of genetics and sex-differential biology in risk for autism

Donna Werling, PhD
Sanders & State Labs, UCSF
October 26, 2016




Autism prevalence is sex-biased

- ~4:1 males:females have a diagnosis of autism spectrum disorder (ASD)



Autism prevalence is sex-biased


- ~4:1 males:females have a diagnosis of autism spectrum disorder (ASD)¹
- 8 males and 3 females in the 11 cases originally reported by Leo Kanner, 1943²
- Male bias consistent over time and across countries¹




¹Fombonne, 2009, *Pediatr Res*. ²Kanner, 1943, *Nervous Child*.

Why study sex bias in ASD from a biological perspective?

Sex appears to be a potent modulator of ASD risk




Males: 1 in 42 diagnosed




Females: 1 in 189 diagnosed

Why study sex bias in ASD from a biological perspective?

Sex appears to be a potent modulator of ASD risk





Males: 1 in 42 diagnosed




Females: 1 in 189 diagnosed

Why study sex bias in ASD from a biological perspective?


Sex appears to be a potent modulator of ASD risk




Female Protective Effect (FPE) Model for ASD = Liability model




Female Protective Effect (FPE) Model for ASD = Liability model




Female Protective Effect (FPE) Model for ASD = *Multiple threshold* liability model




Female Protective Effect (FPE) Model for ASD = *Multiple threshold* liability model





FPE model predicts that diagnosed females carry greater risk than males





FPE model predicts that diagnosed females carry greater risk than males




FPE model predicts that diagnosed females carry greater risk than males




FPE model predicts that diagnosed females carry greater risk than males




FPE model predicts that diagnosed females carry greater risk than males




Higher incidence of disruptive, *de novo* variants in ASD females




Copy number variants (CNVs)¹



Insertion/Deletions (Indels)²





Single nucleotide variants (SNVs)³




¹Sanders et al, 2015, *Neuron*. ²Dong et al, 2014, *Cell Rep*. ³De Rubeis et al, 2014, *Nature*.

Siblings of female cases have higher ASD traits than siblings of male cases




Siblings of female cases have higher ASD traits than siblings of male cases



Autistic traits in siblings?


Mean sex-and-zygosity-normed Z scores

Increase in risk to siblings of female probands




	TEDS	CATSS
■ Siblings of All Non-Probands N(TEDS) = 3,444 N(CATSS) = 5,340	-0.06 (p<0.0001 *§)	-0.05 (p<0.0001 *§)
■ Siblings of Male Probands N(TEDS) = 262 N(CATSS) = 470	0.42 (p=0.002 §)	0.34 (p=0.02 §)
■ Siblings of Female Probands N(TEDS) = 136 N(CATSS) = 230	0.78	0.55


FPE model predicts that females respond differently to liability that is sufficient for diagnosis in males



FPE model predicts that females respond differently to liability that is sufficient for diagnosis in males



FPE model predicts that females respond differently to liability that is sufficient for diagnosis in males



Hypothesis:

Sex-differential biology contributes to male and female differences in ASD risk and/or symptom presentation

1. Quantitative:


Females are protected and have neurotypical phenotype.

2. Qualitative:


Females present symptoms differently than males, and are not diagnosed.

We can use gene expression analysis to identify sex differences that contribute to the FPE

1. Identify genes with sex-differential expression levels in the human brain



2. Characterize the relationship between sex-DEX genes and ASD biology




BRAINSPAN

ATLAS OF THE DEVELOPING HUMAN BRAIN


Table 1 | Periods of human development and adulthood as defined in this study

Period	Description	Age
1	Embryonic	4 PCW \leq Age < 8 PCW
2	Early fetal	8 PCW \leq Age < 10 PCW
3	Early fetal	10 PCW \leq Age < 13 PCW
4	Early mid-fetal	13 PCW \leq Age < 16 PCW
5	Early mid-fetal	16 PCW \leq Age < 19 PCW
6	Late mid-fetal	19 PCW \leq Age < 24 PCW
7	Late fetal	24 PCW \leq Age < 38 PCW
8	Neonatal and early infancy	0 M (birth) \leq Age < 6 M
9	Late infancy	6 M \leq Age < 12 M
10	Early childhood	1 Y \leq Age < 6 Y
11	Middle and late childhood	6 Y \leq Age < 12 Y
12	Adolescence	12 Y \leq Age < 20 Y
13	Young adulthood	20 Y \leq Age < 40 Y
14	Middle adulthood	40 Y \leq Age < 60 Y
15	Late adulthood	60 Y \leq Age


M, postnatal months; PCW, post-conceptional weeks; Y, postnatal years.



There is no evidence of an autosomal gene with XY levels of sexual dimorphism in the brain




There is no evidence of an autosomal gene with XY levels of sexual dimorphism in the brain




Sex-DEX genes identified by permutation approach ($Q \leq 0.05$; top-ranking sex-DEX in ≥ 2 consecutive developmental periods from same brain region):


- Higher expression in males:
 - 505 protein-coding genes, 129 noncoding transcripts
- Higher expression in females:
 - 442 protein-coding genes, 466 noncoding transcripts




Sex-DEX genes are not enriched for neuronal markers




Male-DEX genes show enrichment for microglial and endothelial cell markers




Male-DEX genes show enrichment for microglial and endothelial cell markers




Male-DEX genes show enrichment for microglial and endothelial cell markers




We observe a relationship between sex-DEX genes and ASD biology




We observe a relationship between sex-DEX genes and ASD biology




Enrichment evidence suggests a male sensitization model of ASD risk




Enrichment evidence suggests a male sensitization model of ASD risk



Enrichment evidence suggests a male sensitization model of ASD risk



Enrichment evidence suggests a male sensitization model of ASD risk



Summary

- Intersection of ASD neurobiology and sex-differential neurobiology provides an approach to understand sex bias
- Male-biased expression:
 - Microglial genes
 - Collagen genes and endothelial cell markers
 - Glial genes dysregulated in ASD brain, suggesting a male-sensitization effect
- Validation in independent samples is needed
 - Results are preliminary and based on analysis of a single data set

Looking forward

- Well powered, foundational data sets comparing males and females will be required for:
 - Rigorous validation of sex-differential patterns
 - Thorough investigation of relationships between sex-differential and ASD biology

Data types

- RNA sequencing for gene expression
- ChIP-seq for identifying gene targets of the estrogen and androgen receptors

2x2 design

Developmental stages

- Fetal
- Perinatal
- Early postnatal/childhood
- Puberty
- Adulthood

Cell types

- Neurons
- Microglia
- Astrocytes

Brain regions

- Neocortex
- Thalamus
- Striatum
- Cerebellum

Organisms

- Human
- Primate
- Mouse

Acknowledgements



Stephan
Sanders
UCSF



Matt
State
UCSF



Nenad
Sestan
Yale



Yale

- Forrest Gulden
- Sirisha Pochareddy
- Xuming Xu
- Mingfeng Li
- Rob Kitchen

Allen Brain Institute

- Ed Lein
- Jeremy Miller
- Trygve Bakken

USC

- Jim Knowles

This work was supported by a grant to SS from the Simons Foundation (SFARI #307705), and a fellowship to DW from the Autism Science Foundation (ASF #16-009)

Meeting of the IACC

Afternoon Agenda - continued

3:40 Listening to our Daughters: How Working with Girls and Women on the Spectrum Informs our Understanding of Autism

Kevin Pelphrey, Ph.D.
IACC Member and Panel Chair

4:00 Questions and Discussion

Meeting of the IACC

Panel on Autism in Women and Girls

Meeting of the IACC

Questions and Discussion

Meeting of the IACC

Afternoon Agenda - continued

4:25 Round Robin

4:55 Closing Remarks

5:00 Adjournment

Meeting of the IACC

Round Robin

NIMH Round Robin Update

Joshua Gordon, M.D., Ph.D.

Director, National Institute of Mental Health
Chair, IACC

IACC Full Committee Meeting
October 26, 2016

NIMH ServASD Program

- NIMH responded to the need identified in the IACC Strategic Plan for improved access to and effectiveness of ASD services with the ServASD I request for applications (RFA).
- In 2014, NIMH awarded 12 research grants aimed at testing strategies for early screening, referral and engagement in services for young children, developing service coordination approaches for transition-aged youth, and projects to test strategies to improve and support the community functioning of adults with ASD.
- In October 2015, the ServASD II initiative was re-issued for pilot studies of services strategies for Adults and Youth with ASD. 34 applications were received/reviewed, with awards expected in early 2017.
- <https://grants.nih.gov/grants/guide/rfa-files/RFA-MH-17-200.html>
- <http://grants.nih.gov/grants/guide/rfa-files/RFA-MH-17-205.html>

Round Robin Update

Susan Daniels, Ph.D.

Director, OARC, NIMH and Executive Secretary, IACC

IACC Full Committee Meeting

October 26, 2016

Interagency Committee on Disability Research Draft Government Wide Strategic Plan

- The ICDR invites the general public and other public agencies to comment on the Draft Government Wide Strategic Plan for FY 2017-2020, and the strategic goals and objectives the ICDR will pursue over the next three years.
- <http://icdr.acl.gov/content/icdr-seeks-comments-draft-government-wide-strategic-plan>

Written comments must be received
by **November 4, 2016.**

Meeting of the IACC

Closing Remarks

Meeting of the IACC

Adjournment